Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication

Journal of Clinical Psychopharmacology

Volumn 31, Issue 2, 2011, Pages 180-186

  McClintock, Shawn M ^a,b   Husain, Mustafa M ^a   Wisniewski, Stephen R ^c   Nierenberg, Andrew A ^d   Stewart, Jonathan W ^e   Trivedi, Madhukar H ^a   Cook, Ian ^f   Morris, David ^a   Warden, Diane ^a   Rush, Augustus John ^g  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD UNIVERSITY   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

D; depression; residual; STAR; symptoms; treatment response

Indexed keywords

CITALOPRAM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; DECISION MAKING; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INSOMNIA; LONELINESS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR DISORDER; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY; REMISSION; RESIDUAL DEPRESSION; SELF REPORT; SUICIDAL IDEATION; SYMPTOM; TREATMENT DURATION; WEIGHT CHANGE;

ADULT; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 79952449206     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31820ebd2c     Document Type: Article

References (39)

1. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Survey. Lancet. 2007;370:851-858. (Pubitemid 47362344)
2. Rush AJ. STAR*D: what have we learned? Am J Psychiatry. 2007; 164(2):201-204.
3. Paykel E. Remission and residual symptomatology in major depression. Psychopathology. 1998;31(1):5-14. (Pubitemid 28052440)
4. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221-225. (Pubitemid 29193918)
5. Perlis RH, Nierenberg AA, Alpert JE, et al. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol. 2002;22(5):474-480.
6. Benvenuti A, Rucci P, Calugi S, et al. Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression. Int Clin Psychopharmacol. 2010;25:68-74.
7. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171- 1180.
8. Fava M. Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol. 2006;20(suppl 3):29-34. (Pubitemid 44605930)
9. Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry. 1999;56(9):829-835. (Pubitemid 29420704)
10. Kennedy N, Abbott R, Paykel ES. Remission and recurrence of depression in the maintenance era: long-term outcome in a Cambridge cohort. Psychol Med. 2003;33:827-838. (Pubitemid 36874662)
11. Pintor L, Gasto C, Navarro V, et al. Relapse of major depression after complete and partial remission during a 2-year follow-up. J Affect Disord. 2003;73(3):237-244. (Pubitemid 36120734)
12. Kennedy N, Paykel E. Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord. 2004;80(2-3):135-144. (Pubitemid 38597136)
13. Carney CE, Segal ZV, Edinger JD, et al. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatry. 2007;68(2):254-260. (Pubitemid 46362647)
14. Dombrovski AY, Mulsant BH, Houck PR, et al. Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord. 2007;103(1-3):77-82. (Pubitemid 47445755)
15. Kurian BT, Greer TL, Trivedi MH. Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother. 2009;9(7):975-984.
16. Fava G, Ruini C, Belaise C. The concept of recovery in major depression. Psychol Med. 2007;37(3):307-317.
17. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am. 2003;26(2):457-494. (Pubitemid 36583573)
18. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119-142. (Pubitemid 38230109)
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
20. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: A STAR*D report. Psychol Med. 2010;40(1):41-50.
21. Zimmerman M, Mattia JI. The reliability and validity of a screening questionnaire for 13 DSM-IV Axis I disorders (the Psychiatric Diagnostic Screening Questionnaire) in psychiatric outpatients. J Clin Psychiatry. 1999;60(10):677-683. (Pubitemid 29503648)
22. Zimmerman M, Mattia JI. The Psychiatric Diagnostic Screening Questionnaire: development, reliability and validity. Compr Psychiatry. 2001;42(3):175-189. (Pubitemid 32410920)
23. Rush AJ, Zimmerman M, Wisniewski SR, et al. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord. 2005;87(1):43-55. (Pubitemid 40828202)
24. Rush AJ, Carmody T, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res. 2000;9:45-59.
25. Kobak KA, Greist JH, Jefferson JW, et al. Computerized assessment of depression and anxiety over the telephone using interactive voice response. MD Computing. 1999;16:63-68.
26. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. (Pubitemid 37289444)
27. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation and outcome with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
28. Isacsson G, Rich CL, Jureidini J, et al. The increased use of antidepressants has contributed to the worldwide reduction in suicide rates. Br J Psychiatry. 2010;196:429-433.
29. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide and overall mortality in a nationwide cohort. Arch Gen Psychiatry. 2006;63:1358-1367. (Pubitemid 44878519)
30. Perlis ML, Giles DE, Buysse DJ, et al. Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord. 1997;42(2-3):209-212. (Pubitemid 27170166)
31. Mendlewicz J. Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders. World J Biol Psychiatry. 2009;10(4):269-275.
32. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006;67(11): 1754-1759. (Pubitemid 44955157)
33. Jaeger J, Berns S, Uzelac S, et al. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145(1):39-48. (Pubitemid 44709192)
34. Naismith SL, Longley WA, Scott EM, et al. Disability in major depression related to self-rated and objectively measured cognitive deficits: a preliminary report. BMC Psychiatry. 2007;7:32-38.
35. Holtzheimer PE III, Meeks TW, Kelley ME, et al. A double-blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry. 2008;23(6):625-631. (Pubitemid 351943848)
36. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, et al. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res. 2009;43:855-863.
37. Pedrelli P, Baer L, Losifescu DV, et al. Relationship between residual symptoms of depression and self-reported cognitive impairment. CNS Spectr. 2010;15(1):46-51.
38. Bertschy G, Haffen E, Gervasoni N, et al. Self-rated residual symptoms do not predict 1-year recurrence of depression. Eur Psychiatry. 2010;25:52-57.
39. Taylor DJ, Walters HM, Vittengl JR, et al. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence? J Affect Disord. 2010;123:181-187.